Related Experiment Video
Updated: Jan 29, 2026
06:07
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
Published on: September 2, 2021
2.2K
Bioengineered Cellular and Acellular Therapies for Ischemic Heart Disease in Clinically Relevant Models
Kelsey C Muir1,2, Clark Zheng1,2, Keertana Yalamanchili2
1Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Providence, RI 02903, USA.
Bioengineering (Basel, Switzerland)
|January 28, 2026
Summary
Novel bioengineering strategies like stem cells and extracellular vesicles show promise for treating ischemic heart disease (IHD) by promoting blood vessel growth. Large animal models are crucial for advancing these therapies towards clinical application.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Biomedical Engineering
Background:
- Ischemic heart disease (IHD) is a leading global cause of death and disability.
- Myocardial regenerative capacity is limited, necessitating strategies to preserve heart tissue.
- Current treatments face challenges in clinical translation due to engraftment issues and safety concerns.
Purpose of the Study:
- To review emerging bioengineering approaches for treating IHD.
- To evaluate cellular and acellular therapeutic modalities.
- To highlight the role of large animal models in translational research.
Main Methods:
- Review of cellular therapies (stem/progenitor cells).
- Review of acellular therapies (extracellular vesicles, growth factors, ECM scaffolds).
- Emphasis on large animal models and clinical trial data.
Main Results:
- Bioengineering strategies aim to enhance neovascularization and structural repair in the heart.
- Stem cells, EVs, and matrix scaffolds show potential for myocardial recovery.
- Large animal models are vital for assessing efficacy and safety before human trials.
Conclusions:
- Despite challenges, bioengineering offers promising avenues for IHD treatment.
- Further research in translational models is essential for clinical success.
- Optimizing engraftment, product consistency, and safety are key for future therapies.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
3.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.4K
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
570
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
570
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
215
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
215
01:22Heart Failure VI: Adjunct Therapies
314
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
01:26Heart Failure III: Clinical Manifestations
569
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
569
01:23Rheumatic Heart Disease I: Introduction
510
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
510